These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Hong SH; Avis I; Vos MD; Martínez A; Treston AM; Mulshine JL Cancer Res; 1999 May; 59(9):2223-8. PubMed ID: 10232612 [TBL] [Abstract][Full Text] [Related]
28. Differential regulation of cyclo-oxygenase-2 and 5-lipoxygenase-activating protein (FLAP) expression by glucocorticoids in monocytic cells. Goppelt-Struebe M; Schaefer D; Habenicht AJ Br J Pharmacol; 1997 Oct; 122(4):619-24. PubMed ID: 9375956 [TBL] [Abstract][Full Text] [Related]
29. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Brideau C; Chan C; Charleson S; Denis D; Evans JF; Ford-Hutchinson AW; Fortin R; Gillard JW; Guay J; Guévremont D Can J Physiol Pharmacol; 1992 Jun; 70(6):799-807. PubMed ID: 1330258 [TBL] [Abstract][Full Text] [Related]
30. Synthesis and characterization of a high affinity radioiodinated probe for the alpha 2-adrenergic receptor. Lanier SM; Hess HJ; Grodski A; Graham RM; Homcy CJ Mol Pharmacol; 1986 Mar; 29(3):219-27. PubMed ID: 3005829 [TBL] [Abstract][Full Text] [Related]
31. Lipoxygenase metabolism is required for interleukin-3 dependent proliferation and cell cycle progression of the human M-07e cell line. Miller AM; Allen BS; Ziboh V J Cell Physiol; 1997 Mar; 170(3):309-15. PubMed ID: 9066788 [TBL] [Abstract][Full Text] [Related]
32. Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors. Frenette R; Hutchinson JH; Léger S; Thérien M; Brideau C; Chan CC; Charleson S; Ethier D; Guay J; Jones TR; McAuliffe M; Piechuta H; Riendeau D; Tagari P; Girard Y Bioorg Med Chem Lett; 1999 Aug; 9(16):2391-6. PubMed ID: 10476875 [TBL] [Abstract][Full Text] [Related]
33. Potential anti-inflammatory effects of 5-lipoxygenase inhibition--exemplified by the leukotriene synthesis inhibitor BAY X 1005. Müller-Peddinghaus R J Physiol Pharmacol; 1997 Dec; 48(4):529-36. PubMed ID: 9444606 [TBL] [Abstract][Full Text] [Related]
34. Distinct parts of leukotriene C(4) synthase interact with 5-lipoxygenase and 5-lipoxygenase activating protein. Strid T; Svartz J; Franck N; Hallin E; Ingelsson B; Söderström M; Hammarström S Biochem Biophys Res Commun; 2009 Apr; 381(4):518-22. PubMed ID: 19233132 [TBL] [Abstract][Full Text] [Related]
35. Synthesis of indolylalkoxyiminoalkylcarboxylates as leukotriene biosynthesis inhibitors. Kolasa T; Bhatia P; Brooks CD; Hulkower KI; Bouska JB; Harris RR; Bell RL Bioorg Med Chem; 1997 Mar; 5(3):507-14. PubMed ID: 9113329 [TBL] [Abstract][Full Text] [Related]
36. The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein. Maxis K; Delalandre A; Martel-Pelletier J; Pelletier JP; Duval N; Lajeunesse D Arthritis Res Ther; 2006; 8(6):R181. PubMed ID: 17156456 [TBL] [Abstract][Full Text] [Related]
37. Time-resolved in situ assembly of the leukotriene-synthetic 5-lipoxygenase/5-lipoxygenase-activating protein complex in blood leukocytes. Gerstmeier J; Weinigel C; Rummler S; Rådmark O; Werz O; Garscha U FASEB J; 2016 Jan; 30(1):276-85. PubMed ID: 26396238 [TBL] [Abstract][Full Text] [Related]
38. Regulation of the production and action of leukotrienes by MK-571 and MK-886. Ford-Hutchinson AW Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():9-16. PubMed ID: 1847788 [No Abstract] [Full Text] [Related]
39. Development of novel leukotriene--based anti-asthma drugs: MK-886 and MK-571. Young RN Agents Actions Suppl; 1991; 34():179-87. PubMed ID: 1793062 [TBL] [Abstract][Full Text] [Related]